Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma

Ekenel, Meltem; Keskın, Serkan; Başaran, Mert; Ozdemir, C; Meral, Rasim; Altun, Musa; Aslan, İsmet; Bavbek, Sevil

doi:10.1016/j.oraloncology.2011.04.010

Cited by 23 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 3‐year OS rate was 94.1% after induction chemotherapy followed by chemoradiation, compared with 65% after chemoradiation alone . This superb and exciting result was consistent with that reported in a more recently published, retrospective study: Ekenel et al reported their observation of 59 patients with NPC who received 3 cycles of induction cisplatin (75 mg/m 2 ) and docetaxel (75 mg/m 2 ) followed by combined cisplatin‐based chemotherapy and conventional radiotherapy using cobolt‐60 or a 4 to 6 megavolt linear accelerator. Impressive OS and PFS rates of 94.9% and 84.7%, respectively, were reported.…”

Section: Discussionsupporting

confidence: 85%

“…The effect of docetaxel used with cisplatin and without 5-FU (the TP regimen) for NPC has been addressed in 2 previously reported studies. 23,24 A randomized phase 2 trial published in 2009 studied the toxicities and the primary outcome of patients with NPC who did or did not receive induction chemotherapy using the TP regimen followed by concurrent cisplatin chemotherapy and conventional radiation. In addition to the acceptable adverseeffect profile, the researchers demonstrated a significant improvement in OS for patients who received induction TP chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma

Kong

Niu

et al. 2013

Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma

Kong

Niu

et al. 2013

Cancer

View full text Add to dashboard Cite

show abstract

“…Secondly, only 8.5% of patients achieved CR (in both the primary tumor and nodes) in the current study, while 34 to 46% of patients achieved a CR in the other studies (32)(33). The GEM + NDP regimen was also inferior to the CBP + GEM, docetaxel + CDDP + 5-FU, and docetaxel + CDDP regimens (30,(34)(35)(36)(37)(38), perhaps for similar reasons. Neoadjuvant GEM + NDP did not appear to provide any additional benefit compared with the outcomes of CCRT with CDDP-containing regimens, which were reported by Al-Sarraf et al (3-year PFS and OS rates of ~69 and 76%, respectively) (14) and Wee et al (3-year PFS and OS rates of ~70 and 80%, respectively) (11).…”

Section: C B a Discussionmentioning

confidence: 50%

“…These regimens exhibited good efficacy and tolerable toxicity profiles. However, they failed to significantly improve OS compared with neoadjuvant docetaxel + CDDP + 5-FU (5-fluorouracil; TPF regimen) or neoadjuvant docetaxel + CDDP (TP regimen) (34)(35)(36). However, compared with other regimes, such as neoadjuvant TP or neoadjuvant TPF, the benefits of the GP regimen remain unclear, as the majority of studies had a relatively short follow-up time and small sample size (32)(33)(34)(35)(36)(37)(38).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

2015

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin chemotherapy regimen, followed by concurrent chemoradiotherapy or radiotherapy alone, in locoregionally advanced nasopharyngeal carcinoma (NPC). Eighty-six patients with stage III, IVA or IVB NPC, who received neoadjuvant chemotherapy [gemcitabine, 1,000 mg/m 2 on day 1 (d1) and d5; nedaplatin, 25 mg/m 2 on d 1-3] every 3 weeks for at least two cycles, followed by intensity-modulated radiotherapy every 3 weeks, with or without concurrent nedaplatin (25 mg/m 2 , d1-3) between September 2010 and December 2013, were retrospectively analyzed. By comparing pretreatment and post-treatment MRI images, it was shown that seven patients achieved a complete response (8.5%), while 66 achieved a partial response (80.5%), following completion of neoadjuvant chemotherapy (combined response rate, 89.0%). Grade 3-4 toxicities following neoadjuvant chemotherapy included neutropenia (29.1%), leukopenia (11.6%), liver dysfunction (9.3%), thrombocytopenia (9.3%) and nausea/vomiting (8.1%). The median follow-up was 18 months (range, 5-44 months). The 2-year relapse-free survival, distant metastasis-free survival, progression-free survival and overall survival rates were 96.6, 85.4, 83.3 and 96.1%, respectively. Compared with alternative neoadjuvant chemotherapy regimens in combination with radiotherapy or concurrent chemoradiotherapy, the present gemcitabine and nedaplatin did not provide additional survival benefit and led to a higher frequency of liver dysfunction. Therefore, neoadjuvant gemcitabine and nedaplatin should be used with caution in locoregionally advanced NPC.

show abstract

“…Moreover, withdrawal of capecitabine was associated with satisfactory activity. These results may question the use of 5-fluorouracil or capecitabine within the induction setting, since the combination of cisplatin and docetaxel has proven to be very active [16]. …”

Section: Discussionmentioning

confidence: 99%

Induction Chemotherapy with Docetaxel, Cisplatin and Capecitabine, Followed by Combined Cetuximab and Radiotherapy in Patients with Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck: A Phase I-II Study

Perri¹,

Muto

Argenone

et al. 2013

Oncology

View full text Add to dashboard Cite

Objectives: To replace 5-fluorouracil with capecitabine within a trial of induction chemotherapy followed by cetuximab plus radiotherapy (RT) in patients with locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Also, to replace cisplatin with cetuximab after induction chemotherapy. Methods: Docetaxel and cisplatin were given at 75 mg/m², while capecitabine was initially given at 500 mg/m² twice a day and subsequently escalated. The maximum tolerated dose was used for the phase II study. Results: Seven patients were enrolled. At dose level 1, two dose-limiting toxicities were observed in the first 4 patients (grade 4 neutropenia and grade 3 diarrhea). In both patients, capecitabine was withdrawn and toxicities resolved. Dose escalation was halted and a lower capecitabine dose (750 mg/m² daily) was selected. Two complete responses and five partial responses were observed after induction chemotherapy. Four patients were evaluable for response after cetuximab-RT (3 complete response and 1 partial response). Conclusion: Combined chemoradiotherapy is still the gold standard in LA SCCHN and no studies currently support the use of early induction chemotherapy. Our study did not contribute toward addressing this issue since it was discontinued early because of toxicity.

show abstract

Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma

Cited by 23 publications

References 20 publications

Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma

Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma

Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

Induction Chemotherapy with Docetaxel, Cisplatin and Capecitabine, Followed by Combined Cetuximab and Radiotherapy in Patients with Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck: A Phase I-II Study

Contact Info

Product

Resources

About